Strategies To Overcome and Prevent (STOP) Obesity Alliance
Driving innovative & Practical strategies to combat obesity
The Strategies to Overcome and Prevent (STOP) Obesity Alliance comprises a diverse group of individual, government, advocacy, business, and health organizations dedicated to reversing the obesity epidemic in the United States. Drawing on the strengths of the collaborative, the Alliance conducts research, makes policy recommendations, and develops hands-on tools for providers, advocates, consumers, and policymakers.
What we do to STOP obesity
Conduct Research
Analyze and publish data related to coverage and the costs of obesity, including direct medical and employer-borne costs, but also those related to stigma and bias that impact quality of care.
Develop Tools
Develop research-based patient and health care provider guides to facilitate respectful, productive conversations around weight. Generate reports and guidance that provide essential obesity-related information for policymakers, legislators, and other decision-makers.
Drive Collaboration
Convene key experts for meetings and roundtables to explore and address specific focus areas and barriers to obesity prevention, care, treatment, and coverage, and execute on identified needs.
Sign up for our monthly Newsletter
Subscribe below to receive STOP's monthly email. Each month it is packed with insights from experts in obesity prevention and treatment, details on upcoming events, and exciting news from our member organizations!
Resources
Recent Letters from our Director, Dr. William H. Dietz

Employer Insurance Coverage of Obesity Treatment
May 29, 2025
Limitations in access and coverage of obesity medications has paralleled the advances in the usage of GLP-1s.

Guest Letter: Concerns About Compounded GLP-1 Medications
April 29, 2025
OAC has long advised our members against using compounded GLP-1’s. The main reason is FDA’s own words about compounding.

FDA's New Draft Guidance for Obesity Medications
March 31, 2025
This past January the FDA published a draft guidance entitled “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction.”